# A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes

> **NCT01682902** · PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 43 (actual)

## Conditions studied

- Diabetes
- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Faster-acting insulin aspart
- **DRUG:** Faster-acting insulin aspart
- **DRUG:** insulin aspart

## Key facts

- **NCT ID:** NCT01682902
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2013-03
- **Final completion:** 2013-03
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2017-01-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01682902

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01682902, "A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01682902. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*